Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.9%

3 terminated out of 102 trials

Success Rate

90.3%

+3.8% vs benchmark

Late-Stage Pipeline

4%

4 trials in Phase 3/4

Results Transparency

14%

4 of 28 completed with results

Key Signals

4 with results90% success

Data Visualizations

Phase Distribution

58Total
Not Applicable (39)
Early P 1 (4)
P 1 (6)
P 2 (5)
P 3 (4)

Trial Status

Completed28
Recruiting27
Active Not Recruiting14
Not Yet Recruiting12
Unknown12
Withdrawn3

Trial Success Rate

90.3%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (102)

Showing 20 of 20 trials
NCT07412197Phase 1Not Yet RecruitingPrimary

Preventive Dendritic Cell Vaccination for Lynch Syndrome

NCT02912559Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT05410977Recruiting

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients

NCT07445828Not Yet RecruitingPrimary

Evaluation of Capsule Colonoscopy in Patients With Lynch Syndrome

NCT07542405Not ApplicableNot Yet Recruiting

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

NCT07304063Not ApplicableNot Yet RecruitingPrimary

Overcoming Barriers to Uptake of Cascade Screening

NCT06708429RecruitingPrimary

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT05704010Not ApplicableRecruitingPrimary

Videocapsule Endoscopy in Lynch Syndrome

NCT06654128Not ApplicableCompletedPrimary

The Yield of Artificial Intelligence (GI Genius) in Lynch Syndrome - A Randomized Tandem-colonoscopy Trial

NCT04125914Not ApplicableActive Not Recruiting

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

NCT02359565Phase 1Active Not Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

NCT05419011Phase 2Active Not Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

NCT07163403Phase 1RecruitingPrimary

First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers

NCT03832985Early Phase 1Completed

Pediatric Reporting of Adult-Onset Genomic Results

NCT04407611Not ApplicableCompleted

Scalable Communication Modalities for Returning Genetic Research Results

NCT05692596Active Not Recruiting

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT07472686Recruiting

Small Bowel Capsule Endoscopy in Lynch Syndrome

NCT05677048Not ApplicableActive Not Recruiting

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Scroll to load more

Research Network

Activity Timeline